Page last updated: 2024-08-25

rosiglitazone and fenofibrate

rosiglitazone has been researched along with fenofibrate in 116 studies

Research

Studies (116)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (6.03)	18.2507
2000's	62 (53.45)	29.6817
2010's	42 (36.21)	24.3611
2020's	5 (4.31)	2.80

Authors

Authors	Studies
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM	1
Albrektsen, T; Bury, PS; Din, N; Fleckner, J; Frederiksen, KS; Jeppesen, L; Mogensen, JP; Mortensen, SB; Nehlin, J; Pettersson, I; Sauerberg, P; Svensson, LA; Wassermann, K; Wulff, EM; Ynddal, L	1
Agrawal, AK; Berger, JP; Boueres, JK; Chao, YS; Desai, RC; Doebber, TW; Franklin, R; Heck, JV; Ippolito, MC; Jones, AB; Kelly, LJ; Koyama, H; MacNaul, KL; Miller, DJ; Moller, DE; Sahoo, SP; Wang, PR; Wright, SD; Wu, MS; Zhou, G	1
Henke, BR	1
Becker, JW; Berger, JP; Chao, YS; Doebber, TW; Dropinski, JF; Elbrecht, A; Forrest, M; Heck, JV; Jones, AB; MacNaul, KL; McKeever, BM; Moller, DE; Shi, GQ; Wang, P; Xu, S; Zhou, G	1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Bullock, WH; Burns, M; Chen, L; Claus, T; Daly, M; Dela Cruz, FE; Ehrgott, FJ; Johnson, JS; Livingston, JN; Ma, X; Majumdar, D; Rudolph, J; Schoenleber, RW; Shapiro, J; Tsutsumi, M; Yang, L	1
Chen, X; Cryan, E; Demarest, KT; Hlasta, DJ; Matthews, JM; Rybczynski, PJ; Strauss, K; Tang, Y; Xu, JZ; Yang, M; Zhou, L	1
Chander, R; Chaturvedi, D; Ray, S; Srivastava, AK	1
Chae, YN; Chang, DJ; Jung, JW; Kang, HJ; Kim, MK; Kim, NJ; Koo, BW; Le, TV; Lee, KO; Li, F; Lim, JI; Moon, SH; Paek, SM; Park, HJ; Ryu, JS; Shin, CY; Shin, DH; Suh, YG	1
Acton, JJ; Akiyama, TE; Berger, JP; Chang, CH; Colwell, L; Debenham, S; Doebber, T; Einstein, M; Liu, K; McCann, ME; Meinke, PT; Moller, DE; Muise, ES; Tan, Y; Thompson, JR; Wong, KK; Wood, HB; Wu, M; Xu, L	1
Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB	1
Gavande, N; Hanrahan, JR; Hibbs, DE; Kim, MS; Matin, A; Roubin, RH; Salam, NK; Yang, NX	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Altieri, F; Azzariti, A; Cervoni, L; Crestani, M; Di Giovanni, C; Fracchiolla, G; Gilardi, F; Giudici, M; Guerrini, U; Laghezza, A; Lavecchia, A; Loiodice, F; Mitro, N; Montanari, R; Paradiso, A; Piemontese, L; Pochetti, G; Porcelli, L; Simone, GM; Tortorella, P	1
Dwivedi, AK; Nath, C; Pratap, R; Raghubir, R; Satyanarayana, M; Singh, AB; Singh, H; Singh, SK; Srivastava, AK; Srivastava, M; Srivastava, SP; Tiwari, P; Verma, AK	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Doddareddy, MR; Gavande, N; Groundwater, PW; Hibbs, DE; Matin, A; Nammi, S; Roubin, RH	1
Bu, X; Du, J; Hu, Y; Li, F; Liang, B; Lu, D; Shang, N; Wen, G; Yang, Y; Yu, Y; Yue, X; Zhou, B; Zhuang, W	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y	1
Balaban, S; Cairns, R; Gao, Q; Grewal, T; Groundwater, PW; Hanh, J; Hibbs, DE; Hoy, AJ; Lai, F; Liao, VW; Lin, HY; Ong, JA; Sjöström, H; Váradi, L; Wood, P	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Lei, Y; Li, J; Lin, B; Niu, H; Song, S; Wang, S; Wang, W; Yang, W; Zhao, C; Zhao, Y	1
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y	1
Brunetti, L; Cerchia, C; Genovese, M; Gilardi, F; Laghezza, A; Lavecchia, A; Leuci, R; Loiodice, F; Paoli, P; Piemontese, L; Santi, A; Sblano, S; Thomas, A; Tortorella, P	1
Auwerx, J; Briggs, M; Deeb, S; Heyman, RA; Lefebvre, AM; Peinado-Onsurbe, J; Schoonjans, K; Staels, B	1
Auwerx, J; Briggs, MR; Fievet, C; Fruchart, JC; Lefebvre, AM; Leitersdorf, I; Paterniti, JR; Peinado-Onsurbe, J; Staels, B	1
Auwerx, J; Lefebvre, AM; Martin, G; Schoonjans, K; Staels, B	1
Chinetti, G; Delerive, P; Fadel, A; Fruchart, JC; Habib, A; Koenig, W; Lebret, M; Maclouf, J; Merval, R; Najib, J; Staels, B; Tedgui, A; Torra, IP	1
Andersson, Y; Fruchart, JC; Kosykh, V; Lefebvre, AM; Majd, Z; Martin, G; Najib, J; Sechkin, AV; Staels, B	1
Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T	1
Baugé, E; Chinetti, G; Clavey, V; Copin, C; Dallongeville, J; Fruchart, J; Fruchart, JC; Mariotte, MC; Staels, B	1
Berger, J; Cai, TQ; Li, Y; Shu, H; Wong, B; Woods, JW; Wright, SD; Zhou, G	1
Chaput, E; Edgar, AD; Saladin, R; Silvestre, M	1
Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y	1
Grüb, M; Hombach, V; Kehrle, B; Koenig, W; Kohlhammer, K; Libby, P; Marx, N; Plutzky, J	1
Greenberg, AS; Mathys, JM; Rabbi, MF; Skolnik, PR	1
Amiri, F; Diep, QN; Iglarz, M; Lavoie, MF; Schiffrin, EL; Touyz, RM	1
Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC	1
Gardner, DG; Liang, F; Wang, F; Zhang, S	1
Kim, HS; Kim, MS; Koh, EH; Lee, KU; Park, HS; Park, JY; Youn, JH; Youn, JY	1
Gille, J; Kaufmann, R; Meissner, M; Reisinger, K; Staels, B; Stein, M; Suske, G; Urbich, C	1
Chevillard, G; Clémencet, MC; Etienne, P; Latruffe, N; Martin, P; Nicolas-Francès, V; Pineau, T	1
Desouza, CV; Diez, J; Dunne, B; Fonseca, VA; Matta, AS; McNamara, DB; Murthy, SN	1
Goya, K; Kasayama, S; Kawase, I; Kitamura, T; Kouhara, H; Kurebayashi, S; Saito, H; Sumitani, S; Xu, X; Yamamoto, H	1
Benéteau, N; Chapuis, V; Colpaert, FC; Dupont-Passelaigue, E; Junquéro, D; Lestienne, F; Patoiseau, JF; Rival, Y; Taillandier, T	1
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A	1
Bitter, AD; Demakov, AB; Gunin, AG; Suslonova, NV; Vasilieva, EN	1
Bondy, G; Elliott, T; Frohlich, J; Harris, M; Montaner, J; Normén, L	1
Haas, C; Häring, HU; Kaltenbach, S; Machicao, F; Staiger, H; Stumvoll, M; Weisser, M	1
Barr, R; Bensch, WR; Brozinick, JT; Bull, C; Dana, S; Hawkins, E; Klausing, K; Martin, JA; Otto, K; Rafaeloff-Phail, R; Rafizadeh-Montrose, C; Reifel-Miller, A; Rhodes, G; Robey, R; Rojo, I; Rungta, D; Snyder, D; Warshawsky, A; Wilbur, K; Zhang, T; Zink, R	1
Doebber, TW; Gottesdiener, KM; Larson, PJ; Miller, JL; Moller, DE; Wagner, JA; Weiss, S; Wu, MS	1
Bross, A; Carmona, MC; Casteilla, L; Dacquet, C; Desbazeille, M; Louche, K; Nibbelink, M; Pénicaud, L; Prunet, B; Renard, P	1
Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G	1
Altuntas, Y; Basat, O; Seber, S; Ucak, S	1
Bauer, MF; Francesconi, C; Hohenecker, J; Ledl, M; Roden, M; Roots, I	1
Baik, SH; Choi, DS; Choi, KC; Choi, KM; Kim, HY; Kim, NH; Kim, SG; Lee, KW; Ryu, OH; Seo, JA	1
Albert, AJ; Cong, Z; Gabbay, RA; Gilliland, KL; Liu, W; Mauger, DT; Nelson, AM; Rosamilia, LL; Sivarajah, S; Thiboutot, DM; Trivedi, NR	1
Caguyong, MJ; Cornwell, PD; Dai, X; De Souza, AT; Ulrich, RG	1
Boden, G; Cheung, P; Homko, C; Kresge, K; Mozzoli, M; Zhang, M	1
Andrew, R; Homer, NZ; Karpe, F; Stimson, RH; Tan, GD; Wake, DJ; Walker, BR	1
Clancy, P; Golledge, J; Mangan, S	2
Binder, BR; Blüml, S; Bochkov, VN; Exner, M; Fürnkranz, A; Ikonomu, E; Kadl, A; Krönke, G; Leitinger, N; Sarembock, IJ	1
Stroup, JS	1
Karalliedde, J; Viberti, GC	1
Balakumar, P; Rose, M; Singh, M	1
Aguirre, LE; Draznin, B; Ehlers, LB; Nadeau, KJ; Reusch, JE	1
Baik, SH; Bak, YT; Byun, KS; Choi, KM; Jo, NY; Kim, A; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE	1
Ceska, R; Dobiásová, M; Dolezalová, R; Fait, T; Kasalová, Z; Prázný, M; Stulc, T; Vrablík, M	1
Zhou, JY; Zhou, SW	2
Cong, WN; Liu, GT; Tao, RY; Tian, JY; Ye, F	1
Abbasi, F; Chen, YD; Farin, HM; Lamendola, C; Reaven, GM	1
Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A	1
Fernandez, AB; Thompson, PD; Venero, CV	1
Cheng, B; He, P; Liu, W; Mei, CL; Wan, JJ; Wang, YF	1
Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA	1
Srivastava, RA	2
Ahn, CW; Cha, BS; Kim, HJ; Kim, SK; Lee, HC; Lee, YJ; Ma, ZA; Shim, WS; Zhao, Z	1
Chopra, B; Georgopoulos, NT; Hinley, J; Nicholl, A; Oleksiewicz, MB; Southgate, J	1
Brünner, N; Egerod, FL; Oleksiewicz, MB; Svendsen, JE	1
Bartels, A; Brünner, N; Egerod, FL; Hinley, J; Oleksiewicz, MB; Southgate, J; Svendsen, JE	1
AbdelGawad, H; Baraka, A	1
Chang, YH; Hong, SI; Hong, YJ; Im, M; Kim, M; Lee, DY; Lee, JK; Lee, YY	1
Arora, MK; Balakumar, P; Reddy, K	1
Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y	1
Liu, Q; Niu, YJ; Tao, RY; Tian, JY; Ye, F; Zhu, HB; Zhu, P	1
Chen, W; Liu, HY; Wang, LL; Zhang, LH; Zhou, XB	1
Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY	1
Falk, E; Glien, M; Glombik, H; Herling, AW; Korn, M; Linz, W; Rütten, H; Schäfer, HL; Wendler, W	1
Antonelli, A; Bernini, G; Fallahi, P; Ferrannini, E; Ferrari, SM; Frascerra, S; Gelmini, S; Pupilli, C; Ruffilli, I; Sellari-Franceschini, S	1
Kouroumichakis, I; Liakopoulos, V; Maltezos, E; Mikhailidis, DP; Papanas, N; Zarogoulidis, P	1
Barbieri, M; D'Amico, M; Di Filippo, C; Di Ronza, C; Duan, SZ; Esposito, A; Ferraraccio, F; Marfella, R; Mortensen, RM; Paolisso, G; Rizzo, MR; Rossi, F	1
El-Aidy, Ael-R; Ewais, MM; Samah, M; Tawfik, MK	1
Leung, SW; Man, RY; Qu, C; Vanhoutte, PM	1
Arnould, T; Geeraert, B; Holvoet, P; Hulsmans, M; Tsatsanis, C	1
Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A	1
Chen, L; Huang, W; Park, M; Toborek, M; Zhang, B	1
Aragonès, G; Beltrán-Debón, R; Camps, J; García-Heredia, A; Geeraert, B; Holvoet, P; Joven, J; Pedro-Botet, J; Rodríguez-Gallego, E; Rull, A	1
Arnett, TR; Butters, OR; Patel, JJ	1
Emmett, N; Leander, M; Li, L; Wang, G; Zhang, Y; Zhao, X	1
Aubry, M; Guillouzo, A; Hewitt, P; Jiang, X; Jossé, R; Kopp-Schneider, A; Savary, CC	1
Cui, Y; Deng, M; Qi, ZG; Shang, X; Wang, XL; Xie, ML; Xue, J; Zhang, Y; Zhao, X	1
Ho, HY; Jian, JY; Lin, CH; Shih, CC; Wu, JB	1
Ginsberg, H; He, Y; Heinecke, JW; Oda, M; Reyes-Soffer, G; Ronsein, GE	1
Du, L; Liu, M; Ma, Y; Tang, H; Yan, L	1
Astakhova, AA; Chistyakov, DV; Goriainov, SV; Sergeeva, MG	1
Appay, V; Boddaert, J; Cabral-Piccin, MP; Caputo, A; Clave, E; Dubois, M; Dupré, L; Folcher, V; Frere, JJ; Fusaro, M; Gallerani, E; Gavioli, R; Gostick, E; Llewellyn-Lacey, S; Nicoli, F; Papagno, L; Price, DA; Toubert, A; Vallet, H	1
Chen, Y; Duan, Y; Han, J; Liu, L; Yang, S; Yang, X; Zhang, S	1

Reviews

5 review(s) available for rosiglitazone and fenofibrate

Article	Year
The PPARs: from orphan receptors to drug discovery. Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4 Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2000
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17 Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. Journal of medicinal chemistry, 2020, 05-28, Volume: 63, Issue:10 Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary	2020
Fibrates: therapeutic potential for diabetic nephropathy? European journal of internal medicine, 2012, Volume: 23, Issue:4 Topics: Animals; Creatinine; Diabetic Nephropathies; Disease Progression; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; PPAR alpha; Rosiglitazone; Thiazolidinediones	2012

Trials

7 trial(s) available for rosiglitazone and fenofibrate

Article	Year
Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. Journal of clinical pharmacology, 2005, Volume: 45, Issue:5 Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Cross-Over Studies; Drug Interactions; Fenofibrate; Humans; Hypolipidemic Agents; Lipids; Male; Pilot Projects; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2005
The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes research and clinical practice, 2006, Volume: 71, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipid Metabolism; Middle Aged; PPAR alpha; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides; Uric Acid	2006
Peroxisome proliferator-activated receptors increase human sebum production. The Journal of investigative dermatology, 2006, Volume: 126, Issue:9 Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isotretinoin; Ligands; Lipogenesis; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Sebaceous Glands; Sebum; Thiazolidinediones	2006
Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes, 2007, Volume: 56, Issue:1 Topics: Adiponectin; Blood Glucose; Body Water; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Fenofibrate; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Single-Blind Method; Thiazolidinediones	2007
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:5 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Cortisone; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Fenofibrate; Gas Chromatography-Mass Spectrometry; Hormone Antagonists; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin Resistance; Kinetics; Liver; Male; Metyrapone; Microdialysis; Middle Aged; Mifepristone; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones	2007
Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus. Neuro endocrinology letters, 2008, Volume: 29, Issue:1 Topics: Aged; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Lipoproteins; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Phosphatidylcholine-Sterol O-Acyltransferase; Predictive Value of Tests; Risk Factors; Rosiglitazone; Thiazolidinediones	2008
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects. The American journal of cardiology, 2008, Jul-01, Volume: 102, Issue:1 Topics: Adult; Aged; Blood Glucose; Caloric Restriction; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Fatty Acids, Nonesterified; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides	2008

Other Studies

104 other study(ies) available for rosiglitazone and fenofibrate

Article	Year
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. Bioorganic & medicinal chemistry letters, 2003, Jan-20, Volume: 13, Issue:2 Topics: Animals; Blood Glucose; Glucose Tolerance Test; Insulin; Male; Mice; Models, Molecular; Molecular Conformation; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors	2003
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents. Journal of medicinal chemistry, 2004, Jun-03, Volume: 47, Issue:12 Topics: Animals; Benzopyrans; Chromans; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Macaca mulatta; Male; Mesocricetus; Mice; Phenyl Ethers; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Structure-Activity Relationship; Trans-Activators; Transcription Factors	2004
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. Journal of medicinal chemistry, 2005, Jun-30, Volume: 48, Issue:13 Topics: Animals; Cricetinae; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dogs; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Models, Animal; Models, Molecular; Molecular Structure; Phenylacetates; PPAR alpha; PPAR delta; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship	2005
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy. Journal of medicinal chemistry, 2007, Mar-08, Volume: 50, Issue:5 Topics: Acetates; Animals; Apolipoprotein A-I; Cell Line; Cricetinae; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; In Vitro Techniques; Indans; Lipids; Male; Mice; Mice, Transgenic; PPAR alpha; PPAR delta; PPAR gamma; Radioligand Assay; Rats; Rats, Zucker; Solubility; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation; Triazoles	2007
Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists. Bioorganic & medicinal chemistry letters, 2007, Dec-15, Volume: 17, Issue:24 Topics: Amino Acids; Animals; Butyrates; Combinatorial Chemistry Techniques; Drug Design; Humans; Indans; Mice; Mice, Inbred Strains; Molecular Structure; PPAR alpha; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Urea	2007
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents. Bioorganic & medicinal chemistry, 2008, Mar-01, Volume: 16, Issue:5 Topics: Alkanes; Alkylation; Amination; Animals; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Male; Molecular Structure; Naphthalenes; PPAR gamma; Rats; Structure-Activity Relationship	2008
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. Journal of medicinal chemistry, 2008, Oct-23, Volume: 51, Issue:20 Topics: Animals; Cell Line; Drug Design; Humans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Phenylpropionates; PPAR alpha; PPAR gamma; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation	2008
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w Journal of medicinal chemistry, 2009, Jul-09, Volume: 52, Issue:13 Topics: Animals; Blood Volume; Body Fluids; Diabetes Mellitus, Type 2; Dogs; Haplorhini; Humans; Hypoglycemic Agents; Indoles; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones	2009
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia. Journal of medicinal chemistry, 2009, Jul-23, Volume: 52, Issue:14 Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship	2009
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists. Journal of medicinal chemistry, 2009, Nov-12, Volume: 52, Issue:21 Topics: Benzopyrans; Cell Line; Humans; PPAR alpha; PPAR gamma; Structure-Activity Relationship	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1 Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Partial Agonism; Drug Screening Assays, Antitumor; Fibric Acids; Fibroblasts; Gene Expression Profiling; Humans; Insulin Resistance; Intra-Abdominal Fat; Liver; Mice; Mice, Inbred C57BL; Models, Molecular; PPAR alpha; PPAR gamma; Propionates; Stereoisomerism; Structure-Activity Relationship; Urea	2012
Flavone-based novel antidiabetic and antidyslipidemic agents. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Animals; Biological Availability; Cholesterol; Cricetinae; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Flavones; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Streptozocin; Structure-Activity Relationship; Triglycerides	2012
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists. Bioorganic & medicinal chemistry, 2013, Feb-01, Volume: 21, Issue:3 Topics: Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; HEK293 Cells; Humans; Isoflavones; Models, Molecular; Molecular Structure; Peroxisome Proliferator-Activated Receptors; Structure-Activity Relationship	2013
Synthesis and identification of new flavonoids targeting liver X receptor β involved pathway as potential facilitators of Aβ clearance with reduced lipid accumulation. Journal of medicinal chemistry, 2013, Aug-08, Volume: 56, Issue:15 Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Benzoates; Benzylamines; Brain; Cell Line; Chalcones; Flavones; Hep G2 Cells; Humans; Hydrocarbons, Fluorinated; Lipids; Liver X Receptors; Mice; Mice, Transgenic; Microglia; Molecular Docking Simulation; Orphan Nuclear Receptors; Plaque, Amyloid; Presenilin-1; Promoter Regions, Genetic; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Triglycerides	2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index	2014
Identification of dual PPARα/γ agonists and their effects on lipid metabolism. Bioorganic & medicinal chemistry, 2015, Dec-15, Volume: 23, Issue:24 Topics: 3T3-L1 Cells; Animals; Cell Line; Diabetes Mellitus, Type 2; Drug Design; HEK293 Cells; Humans; Ligands; Lipid Metabolism; Mice; Molecular Docking Simulation; PPAR alpha; PPAR gamma; Small Molecule Libraries	2015
A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular docking studies. European journal of medicinal chemistry, 2017, Sep-29, Volume: 138 Topics: Antioxidants; Chalcones; Coumarins; Dose-Response Relationship, Drug; Drug Design; Fibric Acids; Humans; Molecular Docking Simulation; Molecular Structure; PPAR alpha; PPAR gamma; Structure-Activity Relationship	2017
A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity. European journal of medicinal chemistry, 2022, May-05, Volume: 235 Topics: Cheminformatics; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Lipids; Peroxisome Proliferator-Activated Receptors; PPAR gamma	2022
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. The EMBO journal, 1996, Oct-01, Volume: 15, Issue:19 Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Cell Line; Dimerization; DNA; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoprotein Lipase; Liver; Mice; Mice, Inbred C57BL; Myocardium; Organ Specificity; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation	1996
Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:9 Topics: Adipose Tissue; Animals; Apolipoproteins; Drug Combinations; Fenofibrate; Gene Expression; Hypolipidemic Agents; Lipoprotein Lipase; Lipoproteins; Lipoproteins, VLDL; Liver; Male; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides	1997
Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. The Journal of biological chemistry, 1997, Nov-07, Volume: 272, Issue:45 Topics: 3T3 Cells; Adipose Tissue; Animals; Carrier Proteins; Coenzyme A Ligases; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Mice; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Nuclear Proteins; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured	1997
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 1998, Jun-25, Volume: 393, Issue:6687 Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Humans; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1; Interleukin-6; Isoenzymes; Membrane Proteins; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic	1998
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. Arteriosclerosis, thrombosis, and vascular biology, 1999, Volume: 19, Issue:1 Topics: Aging; Animals; Apolipoprotein C-I; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; Fenofibrate; Gene Expression Regulation; Gene Expression Regulation, Developmental; Humans; Hypolipidemic Agents; Kinetics; Liver; Male; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides	1999
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arteriosclerosis, thrombosis, and vascular biology, 1999, Volume: 19, Issue:6 Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic	1999
Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 1999, Volume: 9, Issue:3 Topics: Animals; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Blood; Carcinoma, Hepatocellular; Cattle; Culture Media; DNA-Binding Proteins; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Liver Neoplasms; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured	1999
Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochemical and biophysical research communications, 2000, Jan-07, Volume: 267, Issue:1 Topics: Cell Nucleus; Cytosol; DNA-Binding Proteins; Fenofibrate; Gene Expression Regulation; Humans; Interleukin-8; Kinetics; Lipopolysaccharides; Matrix Metalloproteinase 9; Monocytes; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured	2000
Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochemical and biophysical research communications, 2000, May-10, Volume: 271, Issue:2 Topics: Acyl-CoA Oxidase; Animals; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins C; Body Weight; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Male; Mice; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Oxidoreductases; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors; Transcription Factors; Triglycerides	2000
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochemical and biophysical research communications, 2000, Nov-30, Volume: 278, Issue:3 Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured	2000
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circulation research, 2002, Apr-05, Volume: 90, Issue:6 Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate; Graft Survival; Heart Transplantation; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Peroxisome Proliferators; Pioglitazone; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha	2002
Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. Journal of acquired immune deficiency syndromes (1999), 2002, Sep-01, Volume: 31, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cell Line; Chromans; Fenofibrate; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages, Alveolar; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha; Virus Replication	2002
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arteriosclerosis, thrombosis, and vascular biology, 2003, Jan-01, Volume: 23, Issue:1 Topics: Animals; Blood Pressure; Body Weight; Endothelin-1; Endothelins; Extracellular Matrix; Fenofibrate; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Oxygen; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tunica Media; Vascular Resistance; Vasodilator Agents	2003
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension (Dallas, Tex. : 1979), 2003, Volume: 42, Issue:4 Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; Endothelins; Fenofibrate; Fibrosis; Heart; Heart Ventricles; Hypertension; Myocardium; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Ventricular Remodeling	2003
Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology, 2003, Volume: 144, Issue:9 Topics: Animals; Animals, Newborn; Base Sequence; Cell Size; Cells, Cultured; Fenofibrate; Gene Expression; Heart Ventricles; Hypertrophy; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Molecular Sequence Data; Mutagenesis, Site-Directed; Myocytes, Cardiac; Natriuretic Peptide, Brain; Peroxisome Proliferators; Pyrimidines; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sarcomeres; Thiazoles; Thiazolidinediones; Transcription Factors	2003
Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes, 2003, Volume: 52, Issue:9 Topics: Adipose Tissue; Animals; Basal Metabolism; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids; Fenofibrate; Glycogen; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Islets of Langerhans; Male; Muscle, Skeletal; Obesity; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Viscera	2003
PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circulation research, 2004, Feb-20, Volume: 94, Issue:3 Topics: Binding Sites; Cell Division; Cells, Cultured; Endothelial Cells; Fenofibrate; Gene Expression Regulation; Humans; Luciferases; Neovascularization, Physiologic; Peroxisome Proliferators; Promoter Regions, Genetic; Protein Binding; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; RNA, Messenger; Rosiglitazone; Sp1 Transcription Factor; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2004
Tissue-specific expression of two peroxisomal 3-ketoacyl-CoA thiolase genes in wild and PPAR alpha-null mice and induction by fenofibrate. Advances in experimental medicine and biology, 2003, Volume: 544 Topics: Acetyl-CoA C-Acyltransferase; Animals; Fenofibrate; Gene Expression; Isoenzymes; Mice; Mice, Knockout; Peroxisomes; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tissue Distribution; Transcription Factors	2003
Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. Journal of cardiovascular pharmacology and therapeutics, 2003, Volume: 8, Issue:4 Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Catheterization; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Fenofibrate; Hyperplasia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Ligands; Models, Cardiovascular; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Triglycerides; Tunica Intima	2003
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:4 Topics: Animals; Aorta; Bezafibrate; Cattle; Cells, Cultured; Dactinomycin; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Fenofibrate; Gene Expression Regulation, Enzymologic; Half-Life; Mifepristone; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection	2004
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. DNA and cell biology, 2004, Volume: 23, Issue:5 Topics: Acetamides; Acetates; Anilides; Cardiovascular Agents; Cell Line; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mevalonic Acid; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tetradecanoylphorbol Acetate; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors	2004
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. Regulatory peptides, 2004, Aug-15, Volume: 120, Issue:1-3 Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2004
Effects of peroxisome proliferator activated receptors-alpha and -gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. The Journal of endocrinology, 2004, Volume: 182, Issue:2 Topics: Animals; beta Catenin; Cell Division; Cytoskeletal Proteins; Estradiol; Estrogen Receptor alpha; Female; Fenofibrate; Immunohistochemistry; Mice; Ovariectomy; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Rosiglitazone; Spectrophotometry; Thiazolidinediones; Trans-Activators; Transcription Factors; Uterus	2004
Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes care, 2004, Volume: 27, Issue:9 Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Female; Fenofibrate; HIV Seropositivity; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2004
Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones. International journal of obesity (2005), 2005, Volume: 29, Issue:7 Topics: Adult; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Fatty Acid Desaturases; Female; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Male; Muscle Fibers, Skeletal; Peroxisome Proliferators; PPAR gamma; Pyrimidines; Receptors, Adiponectin; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Statistics, Nonparametric; Stearoyl-CoA Desaturase; Thiazolidinediones; Troglitazone	2005
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Molecular endocrinology (Baltimore, Md.), 2005, Volume: 19, Issue:6 Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Cinnamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fenofibrate; Gene Expression Regulation, Enzymologic; Glucose; Homozygote; Humans; Hyperlipidemias; In Vitro Techniques; Insulin; Intercellular Signaling Peptides and Proteins; Kinetics; Lipid Metabolism; Liver; Male; Mice; Mice, Transgenic; Models, Chemical; PPAR alpha; PPAR gamma; Protein Binding; Protein Isoforms; Rats; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Triglycerides; Two-Hybrid System Techniques	2005
Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. International journal of obesity (2005), 2005, Volume: 29, Issue:7 Topics: Animals; Body Composition; Depression, Chemical; Drug Therapy, Combination; Fatty Acids; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides; Weight Gain	2005
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:9 Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Animal; Dyslipidemias; Female; Fenofibrate; Foam Cells; Homeostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Macrophages; Mice; Mice, Mutant Strains; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2005
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone. Diabetologia, 2005, Volume: 48, Issue:10 Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Muscular Diseases; Rosiglitazone; Thiazolidinediones	2005
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochemical and biophysical research communications, 2005, Oct-28, Volume: 336, Issue:3 Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Fenofibrate; Gene Expression; Glucose Tolerance Test; Insulin; Intercellular Signaling Peptides and Proteins; Lipids; Male; Nicotinamide Phosphoribosyltransferase; PPAR alpha; PPAR gamma; Rats; Rats, Inbred OLETF; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Viscera	2005
Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle. Toxicological sciences : an official journal of the Society of Toxicology, 2006, Volume: 92, Issue:2 Topics: Animals; Bezafibrate; Fatty Acids; Female; Fenofibrate; Gene Expression Profiling; Glucose; Hypolipidemic Agents; Liver; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; PPAR alpha; Pyrimidines; Rats; Rats, Inbred Strains; Rosiglitazone; Thiazolidinediones; Tretinoin	2006
Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas. Stroke, 2007, Volume: 38, Issue:5 Topics: Aged; Aged, 80 and over; Carotid Stenosis; Female; Fenofibrate; Humans; Ischemic Attack, Transient; Ligands; Lipoproteins; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Signal Transduction; Stroke; Thiazolidinediones; Thromboplastin	2007
Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:6 Topics: Anti-Inflammatory Agents; Cell Proliferation; Cells, Cultured; Chromans; Cyclooxygenase 2; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Induction; Enzyme Inhibitors; Fenofibrate; Heme Oxygenase-1; Humans; Membrane Proteins; Metalloporphyrins; Muscle, Smooth, Vascular; Mutation; Myocytes, Smooth Muscle; Polymorphism, Genetic; PPAR alpha; PPAR gamma; Promoter Regions, Genetic; Protoporphyrins; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Transcription, Genetic; Transfection; Troglitazone; Tumor Necrosis Factor-alpha	2007
Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255. Diabetes, 2007, Volume: 56, Issue:5 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Rosiglitazone; Thiazolidinediones	2007
Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255. Diabetes, 2007, Volume: 56, Issue:5 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Rosiglitazone; Safety; Thiazolidinediones	2007
Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology, 2007, Volume: 80, Issue:2-3 Topics: Analysis of Variance; Animals; Aorta, Abdominal; Blood Pressure; Cardiomegaly; Collagen; Constriction, Pathologic; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Hypoglycemic Agents; Male; Myocardium; Myocytes, Cardiac; Organ Size; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Ventricular Function, Left	2007
Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5 Topics: Animals; Blood Glucose; Fatty Acids; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Triglycerides	2007
Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment. Thrombosis research, 2008, Volume: 121, Issue:6 Topics: Aorta; Atherosclerosis; Blotting, Western; Carotid Stenosis; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fenofibrate; Flow Cytometry; Humans; Ligands; Lipoproteins, LDL; Organ Culture Techniques; Rosiglitazone; Thiazolidinediones; Thrombomodulin; Ultraviolet Rays; Up-Regulation	2008
PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:1 Topics: Animals; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expression Profiling; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; PPAR alpha; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones	2008
Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae. Yao xue xue bao = Acta pharmaceutica Sinica, 2007, Volume: 42, Issue:12 Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Hypoglycemic Agents; Male; PPAR alpha; PPAR delta; PPAR gamma; Rats; Rats, Wistar; Retina; Rosiglitazone; Thiazolidinediones	2007
The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life sciences, 2008, May-07, Volume: 82, Issue:19-20 Topics: Animals; Dietary Fats; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expression; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2008
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. The Journal of pharmacy and pharmacology, 2008, Volume: 60, Issue:9 Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides	2008
Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate. The American journal of medicine, 2008, Volume: 121, Issue:10 Topics: Aged; Cholesterol, HDL; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones	2008
Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways. Cell biology international, 2009, Volume: 33, Issue:3 Topics: Chlamydophila pneumoniae; Cholesterol Esters; Down-Regulation; Fenofibrate; Foam Cells; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Macrophages; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2009
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. Pancreas, 2009, Volume: 38, Issue:3 Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain	2009
Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists. European journal of pharmacology, 2009, Apr-01, Volume: 607, Issue:1-3 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diacylglycerol O-Acyltransferase; DNA-Binding Proteins; Down-Regulation; Drug Interactions; Fenofibrate; Hydrocarbons, Fluorinated; Hyperlipidemias; Hypolipidemic Agents; Liver X Receptors; Male; Mice; Orphan Nuclear Receptors; Phosphoenolpyruvate Carboxykinase (GTP); PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfonamides; Thiazolidinediones; Triglycerides	2009
Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life sciences, 2009, May-08, Volume: 84, Issue:19-20 Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Diabetes Mellitus, Experimental; Diet; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Male; Malonyl Coenzyme A; Muscle, Skeletal; Rats; Rats, Inbred OLETF; Rosiglitazone; Thiazolidinediones	2009
Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. Cell proliferation, 2009, Volume: 42, Issue:5 Topics: Apoptosis; Calcium; Calcium Channels; Caspase 3; Caspase 9; Cell Division; Cells, Cultured; Chromans; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Membrane Potential, Mitochondrial; Oxazines; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptors; Phenoxyacetates; Phenylpropionates; Rosiglitazone; Thiazolidinediones; Troglitazone; Urothelium	2009
PPARalpha and PPARgamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. Journal of applied toxicology : JAT, 2010, Volume: 30, Issue:2 Topics: Animals; Blotting, Western; Female; Fenofibrate; Liver; Male; PPAR alpha; PPAR gamma; Proteins; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Urinary Bladder; Urothelium	2010
PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats. Toxicologic pathology, 2009, Volume: 37, Issue:7 Topics: Administration, Oral; Animals; Carcinogenicity Tests; Carcinogens; Cell Nucleus; Early Growth Response Protein 1; Fenofibrate; Kidney Pelvis; Male; PPAR alpha; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones; Urinary Bladder; Urothelium	2009
Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. Journal of cardiovascular pharmacology and therapeutics, 2010, Volume: 15, Issue:2 Topics: Animals; Apoptosis; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Experimental; Fenofibrate; Hypertrophy, Left Ventricular; Hypolipidemic Agents; Male; Myocytes, Cardiac; Oxidative Stress; PPAR alpha; PPAR gamma; Rats; Rosiglitazone; Streptozocin; Thiazolidinediones	2010
[HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia]. The Korean journal of laboratory medicine, 2010, Volume: 30, Issue:1 Topics: Apolipoprotein A-I; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones	2010
The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. European journal of pharmacology, 2010, Jun-25, Volume: 636, Issue:1-3 Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Interactions; Fenofibrate; Kidney; Lipids; Oxidative Stress; PPAR alpha; PPAR gamma; Proteinuria; Rats; Rosiglitazone; Thiazolidinediones	2010
Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. Planta medica, 2011, Volume: 77, Issue:3 Topics: Adiponectin; Animals; Blood Glucose; Cnidium; Coumarins; Dietary Fats; Dietary Sucrose; Fatty Liver; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Insulin; Insulin Resistance; Lipids; Liver; Male; Peroxisome Proliferator-Activated Receptors; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones	2011
Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver. Fitoterapia, 2011, Volume: 82, Issue:2 Topics: Animals; Antioxidants; Berberine; Coptis; Cyclin T; Cyclin-Dependent Kinase 9; Diabetes Mellitus, Experimental; Diet; Drugs, Chinese Herbal; Enzymes; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Peroxidation; Liver; Male; Malondialdehyde; Phytotherapy; Positive Transcriptional Elongation Factor B; Rats; Rats, Wistar; Rhizome; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Up-Regulation	2011
Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice. The American journal of Chinese medicine, 2010, Volume: 38, Issue:6 Topics: Animals; Area Under Curve; Cordyceps; Deoxyadenosines; Dietary Fats; Disease Models, Animal; Fenofibrate; Glucose; Glucose Clamp Technique; Glucose Intolerance; Insulin; Insulin Resistance; Lipid Metabolism; Lipid Metabolism Disorders; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Phytotherapy; Rosiglitazone; Thiazolidinediones; Weight Gain	2010
Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters. Atherosclerosis, 2011, Volume: 214, Issue:1 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cricetinae; Fatty Acids; Female; Fenofibrate; Hydrocarbons, Fluorinated; Hyperlipidemias; Liver X Receptors; Male; Mesocricetus; Orphan Nuclear Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Sulfonamides; Thiazolidinediones; Triglycerides	2011
Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome. Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:11 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Weight; Drug Synergism; Eating; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipids; Lipoprotein Lipase; Liver; Metabolic Syndrome; Mice; Mice, Inbred ICR; RNA, Messenger; Rosiglitazone; Sodium Glutamate; Thiazolidinediones	2010
Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice. Archives of pharmacal research, 2011, Volume: 34, Issue:4 Topics: Animals; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Rosiglitazone; Thiazolidinediones	2011
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats. Acta pharmacologica Sinica, 2012, Volume: 33, Issue:1 Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Oxazoles; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones	2012
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy. The Journal of endocrinology, 2012, Volume: 213, Issue:2 Topics: Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Fenofibrate; Fibroblasts; Graves Ophthalmopathy; Humans; Interferon-gamma; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2012
Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice. PloS one, 2012, Volume: 7, Issue:4 Topics: Animals; CD36 Antigens; Diet, High-Fat; Fenofibrate; Gene Expression Regulation; Glucose; Lipid Metabolism; Lipid Peroxidation; Mice; Mice, Knockout; Myocytes, Cardiac; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2012
Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. European journal of pharmacology, 2012, Aug-15, Volume: 689, Issue:1-3 Topics: Animals; Antifibrinolytic Agents; Bleomycin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fenofibrate; Male; Pulmonary Fibrosis; Rats; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2012
Wy14643 improves vascular function in the aorta of the spontaneously hypertensive rat mainly by activating peroxisome proliferator-activated receptors alpha. European journal of pharmacology, 2012, Dec-05, Volume: 696, Issue:1-3 Topics: Animals; Aorta, Thoracic; Fenofibrate; Hypertension; In Vitro Techniques; Male; Peroxisome Proliferators; PPAR alpha; PPAR gamma; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Thiazolidinediones; Vasoconstriction	2012
PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. PloS one, 2013, Volume: 8, Issue:4 Topics: Adipocytes; Adiponectin; Animals; Chemokine CCL2; Diet, High-Fat; Fenofibrate; Inflammation; Insulin; Insulin Resistance; Interleukin-1 Receptor-Associated Kinases; Leptin; Macrophages; Mice; Mice, Inbred C57BL; Obesity; Peroxisome Proliferator-Activated Receptors; Plaque, Atherosclerotic; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2013
APOE3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6* Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones	2014
PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:4 Topics: Animals; Astrocytes; Blood-Brain Barrier; Capillary Permeability; Cell Count; Fenofibrate; Male; Matrix Metalloproteinase 9; Mice; Mice, Knockout; Neurons; Neurotoxicity Syndromes; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; tat Gene Products, Human Immunodeficiency Virus; Thiazolidinediones; Tight Junction Proteins	2014
Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study. Journal of proteome research, 2014, Mar-07, Volume: 13, Issue:3 Topics: Animals; Disease Models, Animal; Fatty Liver; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Metabolome; Mice; Mice, Transgenic; Obesity; Peroxisome Proliferator-Activated Receptors; Protein Interaction Mapping; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcriptome	2014
PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell biochemistry and function, 2014, Volume: 32, Issue:4 Topics: Adipogenesis; Animals; Cell Differentiation; Cells, Cultured; Chromans; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Droplets; Metformin; Mice; Osteoblasts; Osteoclasts; Osteogenesis; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone	2014
Altered expression profile of renal α(1D)-adrenergic receptor in diabetes and its modulation by PPAR agonists. Journal of diabetes research, 2014, Volume: 2014 Topics: Animals; Cell Dedifferentiation; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Gene Expression Profiling; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Obesity; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Receptors, Adrenergic, alpha-1; Rosiglitazone; Thiazolidinediones; Up-Regulation	2014
Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicology in vitro : an international journal published in association with BIBRA, 2015, Dec-25, Volume: 30, Issue:1 Pt A Topics: Cell Line; Chromans; Drug Administration Schedule; Fenofibrate; Gene Expression Regulation; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Microarray Analysis; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones; Transcriptome; Troglitazone	2015
PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. Cytokine, 2015, Volume: 75, Issue:1 Topics: Anilides; Animals; Chemokine CCL2; Cytokines; Disease Models, Animal; Fatty Acids, Nonesterified; Fenofibrate; Gene Expression Regulation; Glutathione; Indoles; Inflammation; Interleukin-6; Interleukin-8; Lipid Metabolism; Liver; Male; Malondialdehyde; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Tumor Necrosis Factor-alpha	2015
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana, Prevents Diabetes and Hyperlipidemia by Regulation of Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice. International journal of molecular sciences, 2015, Oct-20, Volume: 16, Issue:10 Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Plants, Medicinal; Rosiglitazone; Thiazolidinediones	2015
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. Molecular & cellular proteomics : MCP, 2016, Volume: 15, Issue:3 Topics: Aged; Apolipoprotein C-II; Aryldialkylphosphatase; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Proteomics; Risk Factors; Rosiglitazone; Thiazolidinediones	2016
Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo. Virology journal, 2017, 05-25, Volume: 14, Issue:1 Topics: Animals; Bezafibrate; DNA, Viral; Enzyme Activators; Enzyme-Linked Immunosorbent Assay; Fenofibrate; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Male; Mice, Inbred BALB C; Models, Animal; Peroxisome Proliferator-Activated Receptors; Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Viral Load; Virus Replication	2017
Comparison of PPAR Ligands as Modulators of Resolution of Inflammation, via Their Influence on Cytokines and Oxylipins Release in Astrocytes. International journal of molecular sciences, 2020, Dec-16, Volume: 21, Issue:24 Topics: Anilides; Animals; Anti-Inflammatory Agents; Astrocytes; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Interleukin-10; Lipopolysaccharides; MAP Kinase Kinase 4; Oxazoles; Oxylipins; p38 Mitogen-Activated Protein Kinases; PPAR gamma; PPAR-beta; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Tumor Necrosis Factor-alpha; Tyrosine	2020
Altered Basal Lipid Metabolism Underlies the Functional Impairment of Naive CD8 Journal of immunology (Baltimore, Md. : 1950), 2022, 02-01, Volume: 208, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aging; Apoptosis; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Division; COVID-19; Female; Fenofibrate; Glucose; HLA-A2 Antigen; Humans; Hypolipidemic Agents; Immunocompetence; Influenza, Human; Lipid Metabolism; Lymphocyte Activation; Male; MART-1 Antigen; Middle Aged; Neoplasms; Peptide Fragments; Rosiglitazone; Single-Blind Method; Vaccination; Viral Vaccines; Young Adult	2022
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate. European journal of pharmacology, 2023, Jan-05, Volume: 938 Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeoxycholic Acid	2023